open access

Vol 4, No 4 (2008)
Review paper
Published online: 2008-10-08
Get Citation

Colorectal cancer - characteristic and treatment resistance

Julita Kulbacka, Jolanta Saczko, Agnieszka Chwiłkowska
Onkol. Prak. Klin 2008;4(4):135-140.

open access

Vol 4, No 4 (2008)
REVIEW ARTICLES
Published online: 2008-10-08

Abstract

Colorectal cancer is a neoplasm with the worst prognosis in Poland. The possibility of cure depends mainly on the stage of disease at diagnosis. The use of chemotherapy is essential in the management of colorectal cancer, but chemotherapy is effective in some patients only due to the resistance to cytotoxic agents. Chemotherapy constitutes usually only part of combined treatment that includes surgery and radiotherapy as well as multidrug resistance modulators and targeted agents. Modern anti-cancer targeted therapies aim at inhibition of molecular oncogenic pathways and selective introduction of active compounds into malignant cells. Novel agents include signal transduction pathways modulators, cell cycle regulators, agents controlling angiogenesis and multidrug resistance, and oncogenes. Anticancer antibodies used either as immunological response modifiers or as an alternative to deliver cytotoxic agents directly to cancer cells play an important role. This therapeutic strategy intends to improve the effectiveness of anticancer treatment with reducing its toxicity. The application of the combined therapies can contribute to the improvement of the treatment in patients.

Abstract

Colorectal cancer is a neoplasm with the worst prognosis in Poland. The possibility of cure depends mainly on the stage of disease at diagnosis. The use of chemotherapy is essential in the management of colorectal cancer, but chemotherapy is effective in some patients only due to the resistance to cytotoxic agents. Chemotherapy constitutes usually only part of combined treatment that includes surgery and radiotherapy as well as multidrug resistance modulators and targeted agents. Modern anti-cancer targeted therapies aim at inhibition of molecular oncogenic pathways and selective introduction of active compounds into malignant cells. Novel agents include signal transduction pathways modulators, cell cycle regulators, agents controlling angiogenesis and multidrug resistance, and oncogenes. Anticancer antibodies used either as immunological response modifiers or as an alternative to deliver cytotoxic agents directly to cancer cells play an important role. This therapeutic strategy intends to improve the effectiveness of anticancer treatment with reducing its toxicity. The application of the combined therapies can contribute to the improvement of the treatment in patients.
Get Citation

Keywords

colorectal cancer; targeted therapy; drug resistance

About this article
Title

Colorectal cancer - characteristic and treatment resistance

Journal

Oncology in Clinical Practice

Issue

Vol 4, No 4 (2008)

Article type

Review paper

Pages

135-140

Published online

2008-10-08

Bibliographic record

Onkol. Prak. Klin 2008;4(4):135-140.

Keywords

colorectal cancer
targeted therapy
drug resistance

Authors

Julita Kulbacka
Jolanta Saczko
Agnieszka Chwiłkowska

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl